$AKTX

U.S. stock indices S&P 500, Nasdaq 100, and Dow Jones hit record highs. Oil prices and Treasury yields eased on U.S.-Iran ceasefire hopes. April's PCE inflation data showed a 3.8% annual increase. IBM plans $10B quantum computing investment. SNOW surged on AWS partnership. LLY rose after CVS restored drug coverage. AKTX highlighted cancer treatment potential. CZR agreed to a $17.6B acquisition.

Akari Therapeutics reported a Q2 2026 net loss of $4.8M, up from $1.9M a year earlier, and said it ended June 30, 2026 with $7.7M cash. The company raised about $8.6M gross proceeds (about $8.0M net) via private placement and warrant exercises. Akari is advancing AKTX-101 toward a planned mid-2027 Phase 1 start.

Akari Therapeutics Plc (AKTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform AKTX-101 advancing through IND-enabling development activities toward planned initiation of P

Akari Therapeutics (AKTX) said it will collaborate with Whitehawk Therapeutics on preclinical studies combining Akari’s PH1 spliceosome-modulating ADC payload with Whitehawk’s TOP1 inhibitor ADC platform. Akari will lead the work to assess dual-payload compatibility and potential synergies. AKTX shares were down 15.07% to $9.10 after a 1-for-40 reverse split on March 30, 2026.

Two U.S. biotech firms, Akston Biosciences and OKAVA Pharmaceuticals, are testing experimental GLP-1 weight-loss treatments for overweight cats. Akston is sponsoring a Cornell study of about 70 cats, while OKAVA is trialing a long-acting implant for up to six months. The drugs are unapproved and results are expected later this year.

Akari Therapeutics Plc (AKTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001541157 0001541157 2026-06-30 2026-06-30 0001541157 AKTX:AmericanDepositarySharesEachRepresenting80000OrdinarySharesMember 2026-06-30 2026-06-30 0001541157 AKTX:OrdinarySharesParValue0.000000005PerShareMember 2026-06-30 2026-06-30 iso4217:USD xbrli:shares iso4217:USD xbr

Akari Therapeutics Plc (AKTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001541157 0001541157 2026-06-23 2026-06-23 0001541157 AKTX:AmericanDepositorySharesEachRepresenting80000OrdinarySharesMember 2026-06-23 2026-06-23 0001541157 AKTX:OrdinarySharesParValue0.000000005PerShareMember 2026-06-23 2026-06-23 iso4217:USD xbrli:shares iso4217:USD xbr

Akari Therapeutics (NASDAQ:AKTX) saw short interest rise to 64,685 shares as of May 15, up from 16,135 on April 30, with about 8.2% of shares sold short and a short-interest ratio of 1.8 days. Armistice Capital bought 2,723,966 shares in Q4, valuing the stake at ~$787,000 (5.95%). Analysts’ consensus is “Hold” with a $89 target. The stock traded at $16.43; EPS missed on May 20.

SciSparc (SPRC) shares rose ~140% after its TSX Venture subsidiary received conditional approval to buy ~54% of private Israeli CliniQuantum for 56.6M NeuroThera shares (~$9.46M). Co-Diagnostics (CODX) gained ~53% for a third day amid Ebola PCR assay progress. Akari (AKTX) jumped ~38% on ASCO abstract acceptance and new KRAS-mutant synergy data; Outlook (OTLK) rose ~26% ahead of a June FDA resubmission.

Akari Therapeutics (NASDAQ: AKTX) announced that its President and CEO, Abizer Gaslightwala, will participate in an investor webcast on May 20, 2026, to discuss the company's differentiated antibody drug conjugate (ADC) pipeline. The presentation will focus on its proprietary PH1 RNA splicing modulator payload platform and the lead TROP2-targeting ADC program, AKTX-101. The event is virtual, with registration available online.